Join Growin Stock Community!
Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-diluted-chart

PFE EPS Diluted

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) diluted EPS in Q1'26 shows a value of 0.47 USD, marking a modest positive figure following a negative Q4'25 result of -0.29 USD. This represents a slight year-over-year decline of approximately -9.6% in EPS growth, indicating ongoing challenges in maintaining profitability momentum into early 2026. Over the period from Q2'23 to Q1'26, PFE's diluted EPS exhibited high volatility, starting with a positive 0.41 USD in Q2'23 before plunging into negative territory with -0.42 USD in Q3'23 and a low of -0.59 USD in Q4'23, then recovering to peaks of 0.78 USD in Q3'24 and stabilizing around 0.50-0.62 USD through Q3'25. Year-over-year EPS growth was predominantly negative, with sharp declines exceeding -75% in early quarters and a notable outlier of +285.7% in Q3'24, but recent periods show erratic patterns including a +50% surge in Q2'25 followed by a steep -514% drop in Q4'25, underscoring inconsistent earnings performance likely influenced by pharmaceutical market dynamics and one-time factors.